Advancements in point-of-care (POC) testing are impacting health systems.
COVID-19 exposed tremendous gaps in health systems and access to testing. Importantly, it also showed the need for rapid and reliable testing to safely reopen schools, return to the workplace and reopen the economy. In this webinar, the featured speaker will review the impact of next-generation POC testing during the pandemic and beyond and explain the science powering this testing technology.
Moving testing from huge, central laboratories to rapid, portable devices has been a pivotal change in medical technology. Previously, testing performance and speed were at odds, but because of recent technological advancements, it’s now possible to deliver both. Next-generation POC testing, different from traditional lateral flow tests, is proving its ability to deliver highly sensitive testing with actionable test results within minutes.
Join this webinar to learn the science and opportunities behind next-generation point-of-care testing and how providers are integrating this into their patient care pathways.
Dr. Nigel Lindner, PhD, Chief Innovation Officer, LumiraDx
Nigel Lindner has a unique combination of scientific, R&D, management and commercial experience, gained across several industries including both professional and consumer diagnostics, and FMCG businesses. Nigel has a successful track record in delivery of innovative products having held several senior roles including CEO of Swiss Precision Diagnostics (SPD), Vice President Global R&D at Alere and senior strategic roles at Unilever R&D.
Who Should Attend?
- Lab Specialists
- POCT Coordinators
- Respiratory Disease Specialists
- Infectious Disease Experts
What You Will Learn
Attendees will learn:
- The science behind next-generation point-of-care (POC) testing allowing it to uniquely combine sensitivity with speed and convenience care pathways
- The clinical performance of the LumiraDx SARS-CoV-2 Antigen Test and its correlation with patient infectivity
- The impact on health systems by providing lab-quality results at the POC and how providers are integrating this into their patient care pathways
LumiraDx develops, manufactures and commercializes an innovative point of care diagnostic Platform, a next generation point of care diagnostic system that combines a small portable Instrument; microfluidic Test Strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform leverages testing methodologies used in lab analyzer systems to deliver lab comparable performance at the point of care in minutes across a broad test menu, in a portable, easy-to-use point of care solution.
LumiraDx recently launched the SARS-CoV-2 Antigen Test for use on the LumiraDx Platform which delivers results in 12 minutes with 97.6% PPA to an EUA approved RT-PCR method within the first 12 days of symptom onset.
In addition to COVID-19 and other tests already available under CE mark, the Platform integrated several testing technologies and sample types into a single Instrument, allowing continued development across a broad test menu.